Q-omics provides the consensus-scored MIR1183 profile across patient tissues and cancer cell-line models. MIR1183 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR1183 is differentially expressed in 2, with the highest sampling consensus in STAD. Additionally, MIR1183 RNA expression shows 8,635 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight READ, STAD, and GBM as cancer lineages where MIR1183 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR1183 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR1183 survival associations across molecular data types. MIR1183 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR1183 RNA expression–survival associations across cancer types. High MIR1183 expression shows unfavorable associations in READ, HNSC, MESO, KIRC, THYM and KICH. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR1183 RNA expression.
This table summarizes MIR1183 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR1183. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR1183 shows lower tumor expression in THCA and higher tumor expression in STAD. The STAD box plot shows higher MIR1183 RNA expression in tumor versus normal tissue (log2 FC = +0.260, t-test p = .031).
This table shows molecular features associated with MIR1183 in patient tissues and cancer cell lines. In patient samples, MIR1183 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
